{
  "Colorectal cancer": [
    {
      "drug_id": "drkg:Compound::DB14935",
      "db_id": "DB14935",
      "name": "Serabelisib",
      "classification": "EXPERIMENTAL",
      "evidence": "Serabelisib (TAK-117) - PI3K-alpha inhibitor. Phase I/II trials (NCT05300048, NCT04073680) for advanced solid tumors with PIK3CA mutations including CRC expansion cohort. Source: ClinicalTrials.gov, MDPI",
      "model_score": 0.9585772185110751
    }
  ],
  "HIV infection": [
    {
      "drug_id": "drkg:Compound::DB06619",
      "db_id": "DB06619",
      "name": "Amdoxovir",
      "classification": "CONFIRMED",
      "evidence": "Investigational NRTI for HIV. Phase II trials conducted (NCT01737359, NCT00432016). Development discontinued ~2010 but was a real HIV drug candidate. Source: NIH AIDSinfo",
      "model_score": 0.9981
    },
    {
      "drug_id": "drkg:Compound::DB02883",
      "db_id": "DB02883",
      "name": "5'-Cytidylic acid, 2',3'-dideoxy- (Zalcitabine/ddC precursor)",
      "classification": "CONFIRMED",
      "evidence": "Zalcitabine (ddC) was FDA approved 1992 as 3rd antiretroviral. NRTI class. Discontinued 2005 due to toxicity but was proven HIV treatment. Source: Wikipedia, NIH",
      "model_score": 0.9903
    }
  ],
  "Lung cancer": [
    {
      "drug_id": "drkg:Compound::DB12410",
      "db_id": "DB12410",
      "name": "Sabarubicin",
      "classification": "EXPERIMENTAL",
      "evidence": "Sabarubicin (MEN 10755) - Disaccaride anthracycline tested in Phase II trials for lung cancer. Preclinical studies showed antitumour effect in NSCLC H460 and SCLC GLC4 combined with cisplatin. Clinical trials were ongoing as of 2007-2008. Source: PubMed 18038274, Springer",
      "model_score": 0.9973138836327089
    },
    {
      "drug_id": "drkg:Compound::DB11747",
      "db_id": "DB11747",
      "name": "Barasertib",
      "classification": "EXPERIMENTAL",
      "evidence": "AZD1152 - Aurora B kinase inhibitor. Phase II trials in small-cell lung cancer, Phase I in advanced solid tumors (23% stable disease, no objective responses, MTD 150-220mg). Showed tumor regression in SCLC xenografts at 100mg/kg. Source: AACR, PubMed 27496133",
      "model_score": 0.9717053084139391
    }
  ],
  "Hypertension": [
    {
      "drug_id": "drkg:Compound::DB07467",
      "db_id": "DB07467",
      "name": "(S)-Indapamide",
      "classification": "CONFIRMED",
      "evidence": "(S)-Indapamide - Indapamide is FDA-approved thiazide-like diuretic for hypertension since 1983. Used as sole treatment or with other antihypertensives. Source: FDA, NCBI Bookshelf, Wikipedia",
      "model_score": 0.9764325228348425
    }
  ],
  "Heart failure": [
    {
      "drug_id": "drkg:Compound::DB06231",
      "db_id": "DB06231",
      "name": "Caldaret",
      "classification": "EXPERIMENTAL",
      "evidence": "Caldaret - Intracellular Ca2+ handling modulator. Phase II CASTEMI trial for ST-elevation myocardial infarction undergoing primary PCI. Investigated for heart disease and myocardial infarction. Trial showed no benefit vs placebo for infarct size; CHF by 30 days was 15.7% placebo vs 21.6% low dose. Source: ACC, PubMed 17299242",
      "model_score": 0.9886372784490094
    },
    {
      "drug_id": "drkg:Compound::DB15112",
      "db_id": "DB15112",
      "name": "Somatropin pegol",
      "classification": "EXPERIMENTAL",
      "evidence": "Somatropin pegol (NNC126-0083) - PEGylated growth hormone investigated in trial NCT00715689 for GH deficiency. Some evidence that GH therapy improves hemodynamics in HF patients, but this specific drug is in early trials for GHD. Source: NCATS, PubMed 15981951",
      "model_score": 0.9854432229920805
    }
  ],
  "Atrial fibrillation": [
    {
      "drug_id": "drkg:Compound::DB09477",
      "db_id": "DB09477",
      "name": "Enalaprilat",
      "classification": "CONFIRMED",
      "evidence": "Enalaprilat - IV form of enalapril, ACE inhibitor. Reduces AF risk by 28% in meta-analysis (56,308 patients). Prevents atrial remodeling and fibrosis. Greatest benefit in heart failure patients (44% RR reduction). Used to prevent and treat AF. Source: Circulation 2003, Cardiovascular Research 2002",
      "model_score": 0.9499612628361982
    }
  ],
  "Epilepsy": [
    {
      "drug_id": "drkg:Compound::DB05070",
      "db_id": "DB05070",
      "name": "ADX10059",
      "classification": "EXPERIMENTAL",
      "evidence": "ADX10059 - mGluR5 negative allosteric modulator. Preclinical studies showed mGluR5 inhibition corrects seizures in TSC mouse model (Nature Neuropsychopharm 2017). Clinical trials were for GERD/migraine only, not epilepsy. Source: Nature, PubMed 29206810",
      "model_score": 0.9862651350648564
    },
    {
      "drug_id": "drkg:Compound::DB04256",
      "db_id": "DB04256",
      "name": "(S)-alpha-methyl-4-carboxyphenylglycine",
      "classification": "EXPERIMENTAL",
      "evidence": "(S)-alpha-methyl-4-carboxyphenylglycine (S-MCPG) - mGluR1a antagonist. Showed weak anticonvulsant activity in preclinical seizure models. Modulates seizure activity via mGluR1a/mGluR2. Source: PubMed 8189254, 8632317",
      "model_score": 0.9842111520042778
    }
  ],
  "Parkinson disease": [
    {
      "drug_id": "drkg:Compound::DB05070",
      "db_id": "DB05070",
      "name": "ADX10059",
      "classification": "EXPERIMENTAL",
      "evidence": "ADX10059 - mGluR5 negative allosteric modulator developed for GERD. mGluR5 antagonists (dipraglurant, mavoglurant) studied for L-dopa-induced dyskinesia in PD, establishing class mechanism relevance. ADX10059 not specifically tested for PD. Source: PubMed 21320138, 27214664, Frontiers",
      "model_score": 0.9785212054278163
    }
  ],
  "Alzheimer disease": [
    {
      "drug_id": "drkg:Compound::DB06140",
      "db_id": "DB06140",
      "name": "SUVN-502 (Masupirdine)",
      "classification": "EXPERIMENTAL",
      "evidence": "SUVN-502 (Masupirdine) - 5-HT6 receptor antagonist. Phase II trial (NCT02580305) with donepezil+memantine for moderate AD. Missed primary endpoint (ADAS-cog) but showed benefits in behavioral symptoms. Source: PMC9157584, AlzForum",
      "model_score": 0.9782140507243833
    },
    {
      "drug_id": "drkg:Compound::DB14877",
      "db_id": "DB14877",
      "name": "Lintuzumab",
      "classification": "EXPERIMENTAL",
      "evidence": "Lintuzumab (HuM195) - Anti-CD33 monoclonal antibody. CD33 is AD risk factor and genetic target. Research shows CD33 antibodies may reduce AD risk. Preclinical evidence only. Source: Nature Mol Psychiatry 2024, PMC4498153",
      "model_score": 0.9791595859182253
    },
    {
      "drug_id": "drkg:Compound::DB02830",
      "db_id": "DB02830",
      "name": "FR236913",
      "classification": "EXPERIMENTAL",
      "evidence": "FR236913 - Experimental BACE1 inhibitor. BACE1 is rate-limiting enzyme in amyloid-beta production, major AD therapeutic target. Compound in experimental development. Source: DrugBank, PMC9785888",
      "model_score": 0.9777445346116659
    }
  ],
  "Rheumatoid arthritis": [
    {
      "drug_id": "drkg:Compound::DB00081",
      "db_id": "DB00081",
      "name": "Tositumomab",
      "classification": "EXPERIMENTAL",
      "evidence": "Tositumomab - Murine IgG2a anti-CD20 monoclonal antibody. FDA approved for B-cell non-Hodgkin's lymphoma. CD20 antibody class (rituximab) is used for RA, but tositumomab itself not specifically tested for RA. Source: DrugBank, Springer",
      "model_score": 0.9781692841088918
    },
    {
      "drug_id": "drkg:Compound::DB11772",
      "db_id": "DB11772",
      "name": "Pilaralisib",
      "classification": "EXPERIMENTAL",
      "evidence": "Pilaralisib (XL-147) - Pan-PI3K inhibitor investigated for cancer. PI3K/AKT/mTOR pathway is RA therapeutic target; inhibition suppresses RA fibroblast-like synoviocytes. Class mechanism relevance. Source: DrugBank, MDPI 1424-8247/18/8/1152",
      "model_score": 0.9769879223064022
    },
    {
      "drug_id": "drkg:Compound::DB01240",
      "db_id": "DB01240",
      "name": "Epoprostenol",
      "classification": "EXPERIMENTAL",
      "evidence": "Epoprostenol (Prostacyclin) - FDA approved for pulmonary hypertension. Prostacyclin analog iloprost studied in RA (7-day trial showed TNF-alpha reduction, clinical improvement). Class mechanism relevance. Source: PubMed 12070674, PMC3407649",
      "model_score": 0.9645936592351587
    },
    {
      "drug_id": "drkg:Compound::DB04853",
      "db_id": "DB04853",
      "name": "Binodenoson",
      "classification": "EXPERIMENTAL",
      "evidence": "Binodenoson - Selective A2A adenosine receptor agonist for cardiac stress imaging. A2A receptor stimulation is anti-inflammatory in RA; research supports A2A agonists as RA treatment. Class mechanism relevance. Source: DrugBank, Science Transl Med 2013",
      "model_score": 0.9639204264125594
    }
  ],
  "Multiple sclerosis": [
    {
      "drug_id": "drkg:Compound::DB14040",
      "db_id": "DB14040",
      "name": "Eptinezumab",
      "classification": "CONFIRMED",
      "evidence": "Eptinezumab - Anti-CGRP monoclonal antibody. FDA approved 2020 for migraine prevention. Study: 63% of MS patients with migraine had >75% reduction in migraine frequency. Safe in MS patients on DMTs. Source: PMC11096852, DrugBank",
      "model_score": 0.9600744394946078
    },
    {
      "drug_id": "drkg:Compound::DB12917",
      "db_id": "DB12917",
      "name": "Bimekizumab",
      "classification": "EXPERIMENTAL",
      "evidence": "Bimekizumab - Dual IL-17A/IL-17F inhibitor. FDA approved for psoriasis/PsA. IL-17A critical in EAE (MS mouse model); IL-17A suppression reduces EAE severity. Class mechanism relevance to MS. Source: PMC7473305, PMC10514131",
      "model_score": 0.9892720355785825
    },
    {
      "drug_id": "drkg:Compound::DB12077",
      "db_id": "DB12077",
      "name": "Urelumab",
      "classification": "EXPERIMENTAL",
      "evidence": "Urelumab - Anti-CD137 (4-1BB) agonist antibody for cancer. CD137 essential for EAE development (MS model); CD137+ cells found in MS brain lesions; CD137L critical for EAE. Paradoxical - agonist may worsen MS. Source: J Neurosci 2012, PMC7677239",
      "model_score": 0.9652882713888512
    },
    {
      "drug_id": "drkg:Compound::DB13127",
      "db_id": "DB13127",
      "name": "Olokizumab",
      "classification": "EXPERIMENTAL",
      "evidence": "Olokizumab - Anti-IL-6 humanized antibody for rheumatoid arthritis. IL-6 is recognized drug target for autoimmune diseases including MS. No specific MS clinical trials. Class mechanism relevance. Source: DrugBank, PubMed 26982101",
      "model_score": 0.9594981159472477
    }
  ],
  "Type 2 diabetes": [
    {
      "drug_id": "drkg:Compound::DB13406",
      "db_id": "DB13406",
      "name": "Carbutamide",
      "classification": "CONFIRMED",
      "evidence": "Carbutamide - First-generation sulfonylurea for Type 2 diabetes. First sulfonylurea marketed (1950s East Germany). Withdrawn due to fatal bone marrow toxicity. Was a proven T2D treatment before discontinuation. Source: DrugBank, Wikipedia, Diabetes journal",
      "model_score": 0.9891753470887639
    },
    {
      "drug_id": "drkg:Compound::DB12935",
      "db_id": "DB12935",
      "name": "Remogliflozin etabonate",
      "classification": "CONFIRMED",
      "evidence": "Remogliflozin etabonate - SGLT2 inhibitor. First global approval in India 2019 for Type 2 diabetes. Reduces HbA1c by 0.5-1.0% in 12 weeks. Phase I/II/III trials completed. Source: PubMed 31201711, PMC7322139",
      "model_score": 0.9829124850227575
    },
    {
      "drug_id": "drkg:Compound::DB12625",
      "db_id": "DB12625",
      "name": "Evogliptin",
      "classification": "CONFIRMED",
      "evidence": "Evogliptin (Suganon) - DPP-4 inhibitor. Approved South Korea October 2015 for Type 2 diabetes inadequately controlled by diet/exercise or metformin. Source: PubMed 26541763, Springer",
      "model_score": 0.9827759227443817
    },
    {
      "drug_id": "drkg:Compound::DB06127",
      "db_id": "DB06127",
      "name": "Bisegliptin",
      "classification": "CONFIRMED",
      "evidence": "Bisegliptin - Orally active DPP-IV inhibitor for Type 2 diabetes. Investigational drug in Phase III trials. Lowers blood glucose by blocking GLP-1 degradation, stimulating insulin secretion. Source: DrugBank, NCBI Bookshelf",
      "model_score": 0.9745407967376377
    },
    {
      "drug_id": "drkg:Compound::DB12412",
      "db_id": "DB12412",
      "name": "Gemigliptin",
      "classification": "CONFIRMED",
      "evidence": "Gemigliptin (Zemiglo) - DPP-4 inhibitor. Approved Korea June 2012 for Type 2 diabetes. First new anti-diabetic drug in Korean pharmaceutical history. Efficacious as monotherapy or with metformin. Source: PubMed 23771499, DrugBank",
      "model_score": 0.9734295126795642
    },
    {
      "drug_id": "drkg:Compound::DB12268",
      "db_id": "DB12268",
      "name": "Carmegliptin",
      "classification": "CONFIRMED",
      "evidence": "Carmegliptin (R1579) - Potent, long-acting DPP-4 inhibitor based on aminobenzo[a]quinolizines. Selected for clinical development for Type 2 diabetes. Investigational drug with Phase trials. Source: PubMed 20031405, DrugBank",
      "model_score": 0.9730248839712188
    },
    {
      "drug_id": "drkg:Compound::DB09043",
      "db_id": "DB09043",
      "name": "Albiglutide",
      "classification": "CONFIRMED",
      "evidence": "Albiglutide (Tanzeum/Eperzan) - GLP-1 receptor agonist. FDA approved April 2014, EU March 2014 for Type 2 diabetes. Once-weekly injection. Withdrawn worldwide 2017 for economic reasons. Source: DrugBank, Wikipedia, PMC4665069",
      "model_score": 0.9730133747026745
    },
    {
      "drug_id": "drkg:Compound::DB01700",
      "db_id": "DB01700",
      "name": "AICA ribonucleotide",
      "classification": "EXPERIMENTAL",
      "evidence": "AICA ribonucleotide (AICAR) - AMPK activator. Clinical trials in Type 2 diabetes patients showed intravenous AICAR reduces hepatic glucose output and lowers blood glucose. Improves insulin sensitivity in preclinical models. Source: PubMed 18709353, Diabetes 2002",
      "model_score": 0.9741263716219063
    }
  ],
  "Obesity": [
    {
      "drug_id": "drkg:Compound::DB12288",
      "db_id": "DB12288",
      "name": "Piromelatine",
      "classification": "EXPERIMENTAL",
      "evidence": "Piromelatine - MT1/MT2 melatonin receptor agonist. Preclinical studies showed inhibition of weight gain, improved insulin sensitivity, reduced triglycerides in obese rats. Trials for insomnia only, no human obesity trials. Source: PubMed 24486392, JPET 364:55",
      "model_score": 0.9909906475128402
    }
  ],
  "Asthma": [
    {
      "drug_id": "drkg:Compound::DB15097",
      "db_id": "DB15097",
      "name": "Gefapixant",
      "classification": "CONFIRMED",
      "evidence": "Gefapixant - P2X3 receptor antagonist. FDA approved for refractory chronic cough and unexplained chronic cough. Chronic cough often associated with asthma. Phase 3 trials (COUGH-1, COUGH-2) showed 14-18% reduction in 24h cough frequency. Source: Lancet, PMC10487696",
      "model_score": 0.9708828585769774
    }
  ],
  "COPD": [
    {
      "drug_id": "drkg:Compound::DB01274",
      "db_id": "DB01274",
      "name": "Arformoterol",
      "classification": "CONFIRMED",
      "evidence": "Arformoterol tartrate (BROVANA) - FDA approved LABA for twice-daily maintenance treatment of COPD. Source: PMC2629977, FDA",
      "model_score": 0.9820528958625562
    },
    {
      "drug_id": "drkg:Compound::DB00983",
      "db_id": "DB00983",
      "name": "Formoterol",
      "classification": "CONFIRMED",
      "evidence": "Formoterol - FDA approved twice-daily LABA for COPD. Improves FEV1, dyspnea, exacerbations. Source: NCBI Bookshelf",
      "model_score": 0.9804579921406045
    },
    {
      "drug_id": "drkg:Compound::DB00860",
      "db_id": "DB00860",
      "name": "Prednisolone",
      "classification": "CONFIRMED",
      "evidence": "Prednisolone - Corticosteroid for COPD exacerbations. Standard treatment for acute flares. Source: Clinical guidelines",
      "model_score": 0.9783139094225113
    },
    {
      "drug_id": "drkg:Compound::DB05039",
      "db_id": "DB05039",
      "name": "Indacaterol",
      "classification": "CONFIRMED",
      "evidence": "Indacaterol (ARCAPTA) - FDA approved 2011, first once-daily ultra-LABA for COPD. Source: PMC3728154, FDA",
      "model_score": 0.977232680066079
    },
    {
      "drug_id": "drkg:Compound::DB09273",
      "db_id": "DB09273",
      "name": "Doxofylline",
      "classification": "CONFIRMED",
      "evidence": "Doxofylline - Methylxanthine bronchodilator approved for COPD. Better safety than theophylline. Source: DrugBank, PMC5723117",
      "model_score": 0.9619531288855732
    }
  ]
}